ArticleTranslational lung cancer research2025
Prognosis of segmentectomy and lobectomy for clinical T1c solid-dominant lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lobectomy, segmentectomy, and wedge resection for elderly patients with solid-predominant stage I NSCLC: survival, pulmonary function, and postoperative outcomes.Translational lung cancer research · 2026Article
- Clinical research advances in thoracic surgery and thoracic oncology in 2025: a panoramic narrative review.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal surgical extent for clinical T1c solid-dominant non-small cell lung cancer (NSCLC) remains debated. This study aimed to compare the recurrence-free survival (RFS) and overall survival (OS) between segmentectomy and lobectomy in patients with clinical T1c solid-dominant NSCLC. Methods: We retrospectively analyzed 888 patients with clinical T1c solid-dominant NSCLC [tumor diameter: 2-3 cm; consolidation-to-tumor ratio (CTR) >0.5] who underwent segmentectomy of the dominant pulmonary segment or lobectomy. Clinical characteristics, 5-year RFS, and 5-year OS were evaluated. Propensity score matching (PSM, 1:1) and subgroup Cox regression models were employed to adjust for confounders. Results: Of the 888 eligible cases, segmentectomy and lobectomy were performed in 55 and 833 patients, respectively. The difference in the 5-year OS between segmentectomy and lobectomy was found to be statistically significant (91.7% Conclusions: The results indicate that segmentectomy of dominant pulmonary segment is superior to lobectomy in terms of OS for solid-dominant NSCLC cases with a tumor diameter between 2 and 3 cm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.